Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-β-cyclodextrin following subcutaneous injection in sheep

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 96-102

  Wu, Zimei ^a   Tucker, Ian G ^b   Razzak, Majid ^c   Yang, Lin ^b   McSporran, Keith ^d   Medlicott, Natalie J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PharmTech Service Limited   (New Zealand)

^d Gribbles Veterinary   (New Zealand)

Author keywords

Hydroxypropyl cyclodextrin; Injection site reactions; Pharmacokinetics; Poorly water soluble drug; Post injection precipitation; Ricobendazole

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALBENDAZOLE SULFOXIDE; CREATINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MUSCLE INJURY; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SHEEP; SKIN TEMPERATURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; BETA-CYCLODEXTRINS; CREATINE KINASE; EXCIPIENTS; FEMALE; INJECTIONS, SUBCUTANEOUS; PHARMACEUTICAL SOLUTIONS; SHEEP; SOLUBILITY;

EID: 77955984579     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.002     Document Type: Article

References (53)

1. Albers E., Müller B. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 1995, 12:311-337.
2. Bevan S., Geppetti P. Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci. 1994, 17:509-512.
3. Brazeau G.A., Cooper B., Svetic K.A., Smith C.L., Gupta P. Current perspectives on pain upon injection of drugs. J. Pharm. Sci. 1998, 87:667-677.
4. Brazeau G.A., Fung H.L. Physicochemical properties of binary organic cosolvent-water mixtures and their relationships to muscle damage following intramuscular injection. J. Parenter. Sci. Technol. 1989, 43:144-149.
5. Brazeau G.A., Fung H.L. Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J. Pharm. Sci. 1990, 79:393-397.
6. Brewster M.E., Vandecruys R., Verreck G., Peeters J. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie 2008, 63:217-220.
7. Chandrasoma P., Taylor C.R. Concise Pathology 1991, Appleton & Lange Prentice-Hall, Norwalk, Conn., CA, pp. 1-50.
8. Chang R.K., Shojaei A.H. Effect of hydroxypropyl-beta-cyclodextrin on drug solubility in water-propylene glycol mixtures. Drug Dev. Ind. Pharm. 2004, 30(3):297-302.
9. Cristofol C., Virkel G., Alvarez L., Arboix M., Lanusse C.E. Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. Biopharm. Drug Dispos. 2000, 21:303-311.
10. Cristofol C., Virkel G., Alvarez L., Sanchez S., Arboix M., Lanusse C. Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. J. Vet. Pharmacol. Ther. 2001, 24:117-124.
11. Dias M.M.R., Raghavan S.L., Pellett M.A., Hadgraft J. The effect of [beta]-cyclodextrins on the permeation of diclofenac from supersaturated solutions. Int. J. Pharm. 2003, 263:173-181.
12. Doenicke A., Roizen M.F., Nebauer A.E., Kugler A., Hoernecke R., Beger-Hintzen H. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth. Analg. 1994, 79:933-939.
13. Formentini E.A., Mestorino O.N., Marino E.L., Errecalde J.O. Pharmacokinetics of ricobendazole in calves. J. Vet. Pharmacol. Ther. 2001, 24:199-202.
14. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis. Concepts and Applications 2000, Swedish Pharmaceutical Press, Stockholm, p. 141. 3rd ed.
15. Gatlin L.A., Gatlin C.A. Formulation and administration techniques to minimise injection pain and tissue damage associated with parenteral products. Injectable Drug Development: Techniques to Reduce Pain and Irritation 1999, 401-420. Interpharm Press Inc., Englewood. P. Gupta, G.A. Brazeau (Eds.).
16. Goudah A. Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. Vet. Res. Commun. 2003, 27:555-566.
17. Iervolino M., Cappello B., Raghavan S.L., Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int. J. Pharm. 2001, 212:131-141.
18. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86:147-162.
19. Kaartinen L., Gips M., Laurila T., Hartel H., Soback S., Pyorala S. Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. Vet. Res. 2000, 31:517-526.
20. Lanusse C.E., Virkel G.L., Sanchez S.F., Alvarez L.I., Lifschitz A.L., Imperiale F., Monfrinotti A. Ricobendazole kinetics and availability following subcutaneous administration of a novel injectable formulation to calves. Res. Vet. Sci. 1998, 65:5-10.
21. Lee C.R., Colovos F.C., Ritzman G.E. Skin temperatures of the pig, goat, and sheep under winter conditions. J. Nutr. 1941, 21:321-326.
22. Lefebvre H.P., Laroute V., Braun J.P., Lassourd V., Toutain P.L. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release. Vet. Res. 1996, 27:343-361.
23. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5:82-85.
24. Manor D., Sadeh M. Muscle fibre necrosis induced by intramuscular injection of drugs. Br. J. Exp. Pathol. 1989, 70:457-462.
25. Masson M., Loftsson T., Masson G., Stefansson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J. Control. Release 1999, 59:107-118.
26. Medlicott N.J., Foster K.A., Audus K.L., Gupta S., Stella V.J. Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J. Pharm. Sci. 1998, 87:1138-1143.
27. Mikaelian I., Poul J.M., Cabanie P. Healing of muscle trauma after intramuscular injection of antibiotics in sheep: correlations between clinical, macroscopic and microscopic scores. Vet. Res. 1996, 27:97-106.
28. Muller R.H., Schmidt S., Buttle I., Akkar A., Schmitt J., Bromer S. SolEmuls(R)-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int. J. Pharm. 2004, 269:293-302.
29. Nagase Y., Arima H., Wada K., Sugawara T., Satoh H., Hirayama F., Uekama K. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: in vitro and in vivo studies. J. Pharm. Sci. 2003, 92:2466-2474.
30. Nagase Y., Hirata M., Arima H., Tajiri S., Nishimoto Y., Hirayama F., Irie T., Uekama K. Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro. J. Pharm. Sci. 2002, 91:2382-2389.
31. Perry C.S., Chiu F.C.K., McIntosh K.A., Prankerd R.J., Charman W.N., Charman S.A. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J. Pharm. Sci. 2006, 95:256-267.
32. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85:1142-1169.
33. Simamora P., Pinsuwan S., Alvarez J.M., Myrdal P.B., Yalkowsky S.H. Effect of pH on injection phlebitis. J. Pharm. Sci. 1995, 84:520-522.
34. Simamora P., Pinsuwan S., Surakitbanharn Y., Yalkowsky S.H. Studies in phlebitis VIII: evaluations of pH solubilized intravenous dexverapamil formulations. PDA J. Pharm. Sci. Technol. 1996, 50:123-128.
35. Sridevi S., Diwan P.V.R. Optimized transdermal delivery of ketoprofen using pH and hydroxypropyl-β-cyclodextrin as co-enhancers. Eur. J. Pharm. Biopharm. 2002, 54:151-154.
36. Stella V.J., He Q. Cyclodextrins. Toxicol. Pathol. 2008, 36:30-42.
37. Stella V.J., Lee H.K., Thompson D.O. The effect of SBE4-[beta]-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: comparison to a co-solvent solution and a water-soluble prodrug. Int. J. Pharm. 1995, 120:197-204.
38. Sutton S.C., Evans L.A., Rinaldi M.T., Norton K.A. Predicting injection site muscle damage. I. Evaluation of immediate release parenteral formulations in animal models. Pharm. Res. 1996, 13:1507-1513.
39. Svendsen O., Carstensen J. Antimicrobiological excipients and local damage at injection site. Toxicol. Lett. 1996, 88:103.
40. Szejtli J. Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: Therefore the increase in number of marketed drug/cyclodextrin formulations is so slow. J. Incl. Phenom. Macro. Chem. 2005, 52:1-11.
41. Torres-Labandeira J.J., Davignon P., Pitha J. Oversaturated solutions of drug in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin. J. Pharm. Sci. 1991, 80:384-386.
42. Toutain P.L., Lassourd V., Costes G., Alvinerie M., Bret L., Lefebvre H.P., Braun J.P. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. J. Vet. Pharm. Ther. 1995, 18:226-235.
43. Tuttle C.B. Intramuscular injections and bioavailability. Am. J. Hosp. Pharm. 1977, 34:965-968.
44. Varady J., Wu X., Wang S. Competitive and reversible binding of a guest molecule to its host in aqueous solution through molecular dynamics simulation: benzyl alcohol/-cyclodextrin system. J. Phys. Chem. B 2002, 106:4863-4872.
45. Ward G.H., Nolan P.E., White M., Yalkowsky S.H. Studies in phlebitis. II. Early detection of amiodarone-induced phlebitis in a rabbit model. Pharm. Res. 1991, 8:801-803.
46. Wilkinson J.H. Clinical significance of enzyme activity measurements. Clin. Chem. 1970, 16:882-890.
47. Wu Z., Razzak M., Tucker I.G., Medlicott N.J. Physicochemical characterization of ricobendazole. I. Solubility, lipophilicity and ionization characteristics. J. Pharm. Sci. 2005, 94:983-993.
48. Wu Z., Tucker I.G., Razzak M., Medlicott N.J. An in vitro kinetic method for detection of precipitation of poorly soluble drugs. Int. J. Pharm. 2005, 304:1-3.
49. Wu Z., Medlicott N.J., Razzak M., Tucker I.G. Development and optimization of a rapid HPLC method for analysis of ricobendazole and albendazole sulfone in sheep plasma. J. Pharm. Biomed. Anal. 2005, 39:225-232.
50. Wu Z., Tucker I.G., Razzak M., Medlicott N.J. Stability of ricobendazole in aqueous solutions. J. Pharm. Biomed. Anal. 2009, 49:1282-1286.
51. Wu Z., Tucker I.G., Razzak M., McSporran K., Medlicott N.J. Tissue compatibility and pharmacokinetics of three potential subcutaneous injectables for low pH drug solutions. J. Pharm. Pharmacol. 2010, 62:873-882.
52. Yalkowsky S.H., Krzyzaniak J.F., Ward G.H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87:787-796.
53. Zannou E.A., Streng W.H., Stella V.J. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm. Res. 2001, 18:1226-1231.